The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Angitia Biopharmaceuticals Announces $120 Million Series C Financing
Dec 11, 2024•over 1 year ago
Contract Type
partnership
Westlake VillageBiotechnologyTherapeutics
Description
Angitia Biopharmaceuticals has closed a $120 million Series C financing round led by Bain Capital Life Sciences with significant participation from new investor Janus Henderson and existing investors. The proceeds will support the development of novel treatments for serious musculoskeletal diseases, including AGA2118, AGA2115, and AGA111.
Company Information
Company
Angitia Biopharmaceuticals
Location
Westlake Village, California, United States
About
Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing novel therapies aimed at improving musculoskeletal health. Angitia is currently developing three biologic product candidates (AGA2118, AGA2115 and AGA111) in the clinic for the treatment of postmenopausal osteoporosis, osteogenesis imperfecta and spinal fusion. Leveraging the team's extensive experience and scientific acumen in bone biology and musculoskeletal drug development, Angitia is committed to developing novel therapeutics based on rational biology and clearly defined unmet medical needs.
Westlake VillageBiotechnologyTherapeutics